CVE-2025-61940
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database.
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.32%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
- CVSS 4.0
- 8.7 HIGHCVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/M
- EPSS
- 0.32% probability · 25th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-603
- Affected
- mirion/biodose\/nmis
- Source
- ics-cert@hq.dhs.gov
References
- https://www.cisa.gov/news-events/ics-medical-advisories/icsma-25-336-01Third Party Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.